Low blood sugar, or hypoglycemia, is when glucose in your blood falls below what your body needs. Ozempic, a brand of semaglutide, lowers blood sugar, so the question is fair. How the drug works is covered in the semaglutide guide.
The short answer depends on what else you take. Here is what the label and the trials show, and who is most likely to run low.
Why Ozempic alone rarely causes a low
Semaglutide makes your pancreas release insulin and cuts glucagon, the hormone that raises blood sugar. The label says it does both “in a glucose-dependent manner” [1].
In plain terms, the push toward more insulin happens when your blood sugar is high. As your sugar falls, that push fades. That built-in brake helps explain why the drug alone seldom sends sugar too low.
The trial numbers show it. In a 30-week trial of Ozempic alone, no one had a severe low [1]. Documented symptomatic lows occurred in 1.6% on 0.5 mg and 3.8% on 1 mg, against 0% on placebo.
When the risk rises: insulin and sulfonylureas
Some diabetes drugs lack that brake. The label singles out insulin and sulfonylureas, a class of pills it calls insulin secretagogues because they push the pancreas to release insulin.
Section 5.5 of the Ozempic label warns that combining it with these drugs “may have an increased risk of hypoglycemia, including severe hypoglycemia” [1].
In a 30-week trial where Ozempic was added to basal insulin, documented symptomatic lows occurred in 29.8% on 1 mg. On placebo with the same insulin, the figure was 15.2%.
With a sulfonylurea, severe lows occurred in 0.8% on 0.5 mg and 1.2% on 1 mg. The label defines a severe low as one where you need another person’s help.
| Setting | Measure | Placebo | Ozempic 0.5 mg | Ozempic 1 mg |
|---|---|---|---|---|
| Ozempic alone, 30 weeks | Documented symptomatic (70 mg/dL or less) | 0% | 1.6% | 3.8% |
| Ozempic alone, 30 weeks | Severe | 0% | 0% | 0% |
| Added to basal insulin, 30 weeks | Documented symptomatic (70 mg/dL or less) | 15.2% | 16.7% | 29.8% |
| Added to basal insulin, 30 weeks | Severe | 0% | 0% | 1.5% |
| With a sulfonylurea | Documented symptomatic | Not reported | 17.3% | 24.4% |
| With a sulfonylurea | Severe | Not reported | 0.8% | 1.2% |
The higher weight-loss dose
Wegovy uses the same molecule at up to 2.4 mg weekly. Its label states plainly that it “lowers blood glucose and can cause hypoglycemia” [2].
STEP 2 tested it for 68 weeks in 1,210 adults with type 2 diabetes and a BMI of 27 or more [3]. The Wegovy label reports this trial as Study 3.
A clinically significant low, under 54 mg/dL, occurred in 6.2% on Wegovy and 2.5% on placebo [2]. The episode rate was 10.7 per 100 patient-years on 2.4 mg, 7.2 on 1 mg and 3.2 on placebo.
One person on Wegovy had a severe low that needed glucose through a vein. No one on placebo did.
If you do not have diabetes
This is where the evidence is thinnest. The Wegovy label says lows “have been reported” with these drugs in adults without type 2 diabetes [2].
But its weight trials in people without diabetes had “no systematic capturing or reporting of hypoglycemia.” So those trials cannot tell you how often it happens.
One trial did count serious lows. In a heart outcomes trial of adults without diabetes, 3 serious episodes occurred on Wegovy and 1 on placebo.
In that trial, people who had had bariatric surgery had more serious lows on Wegovy: 2 of 87 (2.3%), against 0 of 97 on placebo. The label names bariatric surgery as a risk factor for hypoglycemia.
The symptoms to know
The Ozempic Medication Guide lists these signs of low blood sugar [1]:
- dizziness or light-headedness
- blurred vision
- anxiety, irritability or mood changes
- sweating
- slurred speech
- hunger
- confusion or drowsiness
- shakiness or feeling jittery
- weakness or headache
- fast heartbeat
Some of these overlap with ordinary side effects, such as dizziness or headache. The full list of those is in semaglutide side effects.
Who ran low most often
A 2026 case-control study from researchers in Saudi Arabia looked at people with type 2 diabetes on weekly semaglutide [5]. It compared 45 people who had a low with 180 who did not.
A normal BMI and an HbA1c under 7 were linked to a higher chance of a low. People with obesity or an HbA1c above 9 were less likely to have one.
The authors flagged the first three months of treatment for closer monitoring. It is one small study, so treat it as a pointer, not a rule.
Eating much less, or eating on a narrow schedule, is part of this picture for many people. What is known about that is in intermittent fasting and GLP-1 drugs and what to eat on semaglutide.
What the adverse event reports show
A 2021 study searched the FDA’s adverse event reporting system from 2004 to 2020 [4]. It found 1,164 reports of hypoglycemia linked to GLP-1 drugs.
The median time to onset was 5 days after starting. Of those reports, 56.08% involved a hospital stay and 3.53% a death.
Those are shares of reports, not rates. Anyone can file a report, and no one counts the people who took the drug without a problem.
Dehydration from stomach side effects is a separate risk on the same label, covered in can Ozempic cause kidney problems.